On May 28, Honeywell, a globalized digital industrial high-tech enterprise, presented a series of innovative technologies and intelligent solutions in the field of interconnected life science at the 62nd National Pharmaceutical Machinery Expo and 2023 China International Pharmaceutical Machinery Expo (hereinafter referred to as “Pharmaceutical Machinery Expo”), and officially launched the pharmaceutical MES platform (MXP) for the field of life science. Promote the digital transformation of the pharmaceutical industry, and work with customers and partners to promote the construction of a healthy China.

The Pharmaceutical MES Platform (MXP), which Honeywell launched at Mesa, has the advantage of a flexible modular platform that covers all stages from clinical trials to commercial product development, enabling life sciences manufacturing companies of all sizes to accelerate digital transformation to improve efficiency, quality and compliance. The platform enables digitization of paper processes and seamless integration with current systems, enabling pharmaceutical and biologic manufacturers to accelerate innovation through real-time batch reporting, audit responses, and continuous quality and process improvement. With embedded analytics and real-time batch comparison capabilities, the platform provides accurate and fast intelligence that allows users to detect and intervene on delays relative to gold batches, preventing batch losses, shortening drug time-to-market and improving product quality.

TSXCUSBMBP

TSXCUSBMBP

TSXCUSBMBP

“China’s pharmaceutical industry has entered the fast track of development, and digitalization will become an important path to lead the transformation and upgrading of pharmaceutical enterprises and promote the high-quality development of the pharmaceutical sector.” “Life sciences and healthcare is one of Honeywell’s key growth areas, and we provide industry-leading solutions for drug discovery, packaging, manufacturing and management processes,” said Jiang Zhao, general manager of Project automation and Solutions for Honeywell Process Control in China. This launch of the Pharmaceutical MES Platform (MXP) shows Honeywell’s mature solutions covering pharmaceutical research and development, manufacturing and post-regulatory, in an effort to help more upstream and downstream companies with digital technology, and inject new vitality into the intelligent development of the pharmaceutical industry.”

Honeywell has the technology, expertise and customer service to cover the whole value chain of life sciences, providing customers with mature solutions in all aspects of medical innovation research, development and delivery, and promoting the development of life sciences with innovative technology. The company helps usher in a new future for medicine and medical devices through cutting-edge technologies, specialty chemicals and high-performance materials, and promotes transparency and tracking of product information through technological innovation to support timely, compliant and safe delivery of medical products. At the same time, Honeywell’s proven technology simplifies manufacturing processes, increases efficiency and accelerates the delivery of quality medical products to patients.

In China, Honeywell continues to promote innovative technology research and development in the field of life sciences based on its global wealth of resources and business network advantages, and actively carries out in-depth cooperation with leading enterprises to help the life sciences industry realize digital intelligent transformation. For example, during the China International Import Expo in 2022, Honeywell entered into cooperation with Tonghua Angrui Biopharma Co., LTD., Zhejiang Xianju Junye Pharmaceutical Co., LTD., Shanghai Haishun New Pharmaceutical Packaging Materials Co., LTD., and other enterprises to enable smart factory construction and digital production with excellent operation management system, and promote the smart manufacturing upgrade of the pharmaceutical industry.

Honeywell will take this release of pharmaceutical MES Platform (MXP) as an opportunity to continue to commit to the implementation of the localization development strategy of “East serves East”, join hands with multiple partners, continue to promote the digital and intelligent transformation and upgrading of the pharmaceutical industry, and help create a new digital ecology of Chinese pharmaceutical.